Mycobacterium tuberculosis (Mtb) is one of the world's most successful pathogens. WHO estimates that about one third of the world's population has a positive skin test that reflects a long-term adaptive immune response to Mtb antigens. These individuals are considered to have actual or potential latent Mtb infection (LTBl). Among them, a minority that cannot be identified prospectively will develop reactivation tuberculosis (TB) despite having apparently normal immunity. Active TB can be contagious both to those who were previously unexposed and those with LTBl and is usually lethal if untreated. Adequate numbers of CD4 T cells, tumor necrosis factor alpha (TNF?), and interferon-gamma (IFN?) are validated determinants of control of primary TB, but the vast majority of HIV negative patients with reactivation TB do not have defined defects in these pathways. The ability of Mtb to remain latent within the human host, and the related failure of the human immune system to sterilize Mtb in latently infected individuals, are poorly understood. Antimicrobial therapy for active infection by drug-sensitive Mtb is effective, but current drugs must be given for 6 months to achieve relapse-free cure rates of >95%. The necessity for this prolonged duration of therapy is attributable to the ability of genetically drug-sensitive Mtb to adopt a phenotypically drug-tolerant, persistent state in which it is not readily sterilized by current drugs. Despite substantal efforts to understand these two critical features of Mtb infection-latency and persistence-fundamental questions remain about the genetic, immunologic, and microbiologic contributors to both. We seek to close this knowledge gap through a Tuberculosis Research Unit (TBRU) that unites investigators at Weill Cornell Medical College (WCMC), Rockefeller University (RU), and Memorial Sloan Kettering Cancer Center (MSKCC), with selected external collaborators, and draws on patients at the WMC-affiliated GHESKIO Centers in Haiti to provide insight into latency and persistence of Mtb during human infection.

Public Health Relevance

This multi-institutional TBRU will deliver new insights into the ability of M. tuberculosis to resist elimination by the human immune system during latency and by antimicrobials during drug treatment for tuberculosis.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Sizemore, Christine F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Weill Medical College of Cornell University
Schools of Medicine
New York
United States
Zip Code
Ocheretina, Oksana; Byrt, Erin; Mabou, Marie-Marcelle et al. (2016) False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagn Microbiol Infect Dis 85:53-5
Warrier, Thulasi; Kapilashrami, Kanishk; Argyrou, Argyrides et al. (2016) N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:E4523-30
Glickman, Michael S; Schluger, Neil (2016) Adding Insult to Injury: Exacerbating TB Risk with Smoking. Cell Host Microbe 19:432-3
Gold, Ben; Smith, Robert; Nguyen, Quyen et al. (2016) Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. J Med Chem 59:6027-44
Lupoli, Tania J; Fay, Allison; Adura, Carolina et al. (2016) Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK. Proc Natl Acad Sci U S A 113:E7947-E7956
Nathan, Carl (2015) What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev 264:2-5
Nathan, Carl; Barry 3rd, Clifton E (2015) TB drug development: immunology at the table. Immunol Rev 264:308-18
Ocheretina, Oksana; Shen, Lishuang; Escuyer, Vincent E et al. (2015) Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a ""Low-Level"" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation. PLoS One 10:e0129207
Gold, Ben; Roberts, Julia; Ling, Yan et al. (2015) Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:6521-38
Severe, Linda; Fitzgerald, Daniel W; Deschamps, Marie M et al. (2014) ""I am proud of myself, just the way I am"" (Mwen fyé de tét mwen, jan mwen ye ya): a qualitative study among young Haitian women seeking care for sexually transmitted infections (STIs) in Haiti. AIDS Educ Prev 26:158-69